Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology

Journal of Medicinal Chemistry

Volumn 59, Issue 5, 2016, Pages 1840-1853

  Morales, Paula ^a   Whyte, Lauren S ^b   Chicharro, Roberto ^a   Gómez Cañas, María ^c,d,e   Pazos, M Ruth ^c,d,e   Goya, Pilar ^a   Irving, Andrew J ^f   Fernández Ruiz, Javier ^c,d,e   Ross, Ruth A ^b   Jagerovic, Nadine ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^e INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^f UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55 AGONIST; G PROTEIN COUPLED RECEPTOR ANTAGONIST; LIGAND; UNCLASSIFIED DRUG; GPR55 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE;

AGONIST; ARTICLE; CELL IMPEDANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; IMPEDANCE; SIGNAL TRANSDUCTION; TECHNOLOGY; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENZYME ASSAY; HEK293 CELL LINE; METABOLISM; PROCEDURES; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC IMPEDANCE; ENZYME ASSAYS; HEK293 CELLS; HUMANS; MOLECULAR STRUCTURE; PYRAZOLES; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84960880002     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01331     Document Type: Article

References (61)

1. Sawzdargo, M.; Nguyen, T.; Lee, D. K.; Lynch, K. R.; Cheng, R.; Heng, H. H. Q.; George, S. R.; O'Dowd, B. F. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, psi GPR53 and GPR55: GPR55 is extensively expressed in human brain Mol. Brain Res. 1999, 64, 193-198 10.1016/S0169-328X(98)00277-0
2. Drmota, T.; Greasley, P.; Groblewski, T. (AstraZeneca) Screening assays for cannabinoid- ligand-type modulators of GPR55., WO2004/0748844, 2004.
3. Brown, A. J.; Wise, A. (Glaxosmithkline) Identification of modulators of GPR55 activity, WO2001/86305A2, 2001.
4. Zhao, P.; Abood, M. E. GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors Life Sci. 2013, 92, 453-457 10.1016/j.lfs.2012.06.039
5. Shore, D. M.; Reggio, P. H. The therapeutic potential of orphan GPCRs, GPR35 and GPR55 Front. Pharmacol. 2015, 6, 1-22 10.3389/fphar.2015.00069
6. Ross, R. A. The enigmatic pharmacology of GPR55 Trends Pharmacol. Sci. 2009, 30, 156-163 10.1016/j.tips.2008.12.004
7. Ryberg, E.; Larsson, N.; Sjögren, S.; Hjorth, S.; Hermansson, N.-O.; Leonova, J.; Elebring, T.; Nilsson, K.; Drmota, T.; Greasley, P. J. The orphan receptor GPR55 is a novel cannabinoid receptor Br. J. Pharmacol. 2007, 152, 1092-1101 10.1038/sj.bjp.0707460
8. Johns, D. G.; Behm, D. J.; Walker, D. J.; Ao, Z.; Shapland, E. M.; Daniels, D. A.; Riddick, M.; Dowell, S.; Staton, P. C.; Green, P.; Shabon, U.; Bao, W.; Aiyar, N.; Yue, T.-L.; Brown, A. J.; Morrison, A. D.; Douglas, S. A. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects Br. J. Pharmacol. 2007, 152, 825-831 10.1038/sj.bjp.0707419
9. GPR18, GPR55 and GPR119: GPR55. IUPHAR/BPS Guide to Pharmacology. http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=114.
10. Pertwee, R. G.; Howlett, A. C.; Abood, M. E.; Alexander, S. P. H.; Di Marzo, V.; Elphick, M. R.; Greasley, P. J.; Hansen, H. S.; Kunos, G.; Mackie, K.; Mechoulam, R.; Ross, R. A. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 Pharmacological Reviews 2010, 62, 588-631 10.1124/pr.110.003004
11. Sharir, H.; Abood, M. E. Pharmacological characterization of GPR55, a putative cannabinoid receptor Pharmacol. Ther. 2010, 126, 301-313 10.1016/j.pharmthera.2010.02.004
12. Moriconi, A.; Cerbara, I.; Maccarrone, M.; Topai, A. GPR55: Current knowledge and future perspectives of a purported "Type-3" cannabinoid receptor Curr. Med. Chem. 2010, 17, 1411-1429 10.2174/092986710790980069
13. Nevalainen, T.; Irving, A. J. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity? Curr. Top. Med. Chem. 2010, 10, 799-813 10.2174/156802610791164229
14. Elbegdorj, O.; Westkaemper, R. B.; Zhang, Y. A homology modeling study toward the understanding of three-dimensional structure and putative pharmacological profile of the G-protein coupled receptor GPR55 J. Mol. Graphics Modell. 2013, 39, 50-60 10.1016/j.jmgm.2012.10.005
15. Staton, P. C.; Hatcher, J. P.; Walker, D. J.; Morrison, A. D.; Shapland, E. M.; Hughes, J. P.; Chong, E.; Mander, P. K.; Green, P. J.; Billinton, A.; Fulleylove, M.; Lancaster, H. C.; Smith, J. C.; Bailey, L. T.; Wise, A.; Brown, A. J.; Richardson, J. C.; Chessell, I. P. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain Pain 2008, 139, 225-236 10.1016/j.pain.2008.04.006
16. Moreno-Navarrete, J. M.; Catalán, V.; Whyte, L.; Díaz-Arteaga, A.; Vázquez-Martínez, R.; Rotellar, F.; Guzmán, R.; Gómez-Ambrosi, J.; Pulido, M. R.; Russell, W. R.; Imbernón, M.; Ross, R. a; Malagón, M. M.; Dieguez, C.; Fernández-Real, J. M.; Frühbeck, G.; Nogueiras, R. The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity Diabetes 2012, 61, 281-291 10.2337/db11-0649
17. Daly, C. J.; Ross, R. a; Whyte, J.; Henstridge, C. M.; Irving, a J.; McGrath, J. C. Fluorescent ligand binding reveals heterogeneous distribution of adrenoceptors and "cannabinoid-like" receptors in small arteries Br. J. Pharmacol. 2010, 159, 787-796 10.1111/j.1476-5381.2009.00608.x
18. Whyte, L. S.; Ryberg, E.; Sims, N. A.; Ridge, S. A.; Mackie, K.; Greasley, P. J.; Ross, R. A.; Rogers, M. J. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 16511-16516 10.1073/pnas.0902743106
19. Leyva-Illades, D.; De Morrow, S. Orphan G protein receptor GPR55 as an emerging target in cancer therapy and management Cancer Manage. Res. 2013, 5, 147-155 10.2147/CMAR.S35175
20. Ford, L. A.; Roelofs, A. J.; Anavi-Goffer, S.; Mowat, L.; Simpson, D. G.; Irving, A. J.; Rogers, M. J.; Rajnicek, A. M.; Ross, R. A. A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells Br. J. Pharmacol. 2010, 160, 762-771 10.1111/j.1476-5381.2010.00743.x
21. Andradas, C.; Caffarel, M. M.; Pérez-Gómez, E.; Salazar, M.; Lorente, M.; Velasco, G.; Guzmán, M.; Sánchez, C. The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK Oncogene 2011, 30, 245-252 10.1038/onc.2010.402
22. Anavi-Goffer, S.; Baillie, G.; Irving, A. J.; Gertsch, J.; Greig, I. R.; Pertwee, R. G.; Ross, R. A. Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids J. Biol. Chem. 2012, 287, 91-104 10.1074/jbc.M111.296020
23. Henstridge, C. M.; Balenga, N. A. B.; Ford, L. A.; Ross, R. A.; Waldhoer, M.; Irving, A. J. The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation FASEB J. 2009, 23, 183-193 10.1096/fj.08-108670
24. Ross, R. A. L-α-lysophosphatidylinositol meets GPR55: a deadly relationship Trends Pharmacol. Sci. 2011, 32, 265-269 10.1016/j.tips.2011.01.005
25. Oka, S.; Nakajima, K.; Yamashita, A.; Kishimoto, S.; Sugiura, T. Identification of GPR55 as a lysophosphatidylinositol receptor Biochem. Biophys. Res. Commun. 2007, 362, 928-934 10.1016/j.bbrc.2007.08.078
26. Oka, S.; Toshida, T.; Maruyama, K.; Nakajima, K.; Yamashita, A.; Sugiura, T. 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55 J. Biochem. 2008, 145, 13-20 10.1093/jb/mvn136
27. Yin, H.; Chu, A.; Li, W.; Wang, B.; Shelton, F.; Otero, F.; Nguyen, D. G.; Caldwell, J. S.; Chen, Y. A. Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay J. Biol. Chem. 2009, 284, 12328-12338 10.1074/jbc.M806516200
28. Pertwee, R. G. GPR55: a new member of the cannabinoid receptor clan? Br. J. Pharmacol. 2007, 152, 984-986 10.1038/sj.bjp.0707464
29. Kapur, A.; Zhao, P.; Sharir, H.; Bai, Y.; Caron, M. G.; Barak, L. S.; Abood, M. E. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands J. Biol. Chem. 2009, 284, 29817-29827 10.1074/jbc.M109.050187
30. Lauckner, J. E.; Jensen, J. B.; Chen, H.-Y.; Lu, H.-C.; Hille, B.; Mackie, K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 2699-26704 10.1073/pnas.0711278105
31. Heynen-Genel, S.; Dahl, R.; Shi, S.; Milan, L.; Hariharan, S.; Bravo, Y.; Sergienko, E.; Hedrick, M.; Dad, S.; Stonich, D.; Su, Y.; Vicchiarelli, M.; Mangravita-Novo, A.; Smith, L. H.; Chung, T. D.; Sharir, H.; Barak, L. S.; Abood, M. E. Screening for Selective Ligands for GPR55-Agonists. In Probe Reports from the NIH Molecular Libraries Program [Online]. National Center for Biotechnology Information: Bethesda, MD, 2010. http://www.ncbi.nlm.nih.gov/books/NBK66152/ (accessed June 10, 2015).
32. Heynen-Genel, S.; Dahl, R.; Shi, S.; Milan, L.; Hariharan, S.; Sergienko, E.; Hedrick, M.; Dad, S.; Stonich, D.; Su, Y.; Vicchiarelli, M.; Mangravita-Novo, A.; Smith, L. H.; Chung, T. D.; Sharir, H.; Caron, M. G.; Barak, L. S.; Abood, M. E. Screening for Selective Ligands for GPR55-Antagonists. In Probe Reports from the NIH Molecular Libraries Program [Online]. National Center for Biotechnology Information: Bethesda, MD, 2010. http://www.ncbi.nlm.nih.gov/books/NBK66153/ (accessed June 10, 2015).
33. Brown, A. J.; Daniels, D. a; Kassim, M.; Brown, S.; Haslam, C. P.; Terrell, V. R.; Brown, J.; Nichols, P. L.; Staton, P. C.; Wise, A.; Dowell, S. J. Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist J. Pharmacol. Exp. Ther. 2011, 337, 236-246 10.1124/jpet.110.172650
34. Kargl, J.; Brown, A. J.; Andersen, L.; Dorn, G.; Schicho, R.; Waldhoer, M.; Heinemann, A. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function J. Pharmacol. Exp. Ther. 2013, 346, 54-66 10.1124/jpet.113.204180
35. Paul, R. K.; Wnorowski, A.; Gonzalez-Mariscal, I.; Nayak, S. K.; Pajak, K.; Moaddel, R.; Indig, F. E.; Bernier, M.; Wainer, I. W. (R,R′)-4′-methoxy-1-naphthylfenoterol targets GPR55-mediated ligand internalization and impairs cancer cell motility Biochem. Pharmacol. 2014, 87, 547-561 10.1016/j.bcp.2013.11.020
36. Cumella, J.; Hernández-Folgado, L.; Girón, R.; Sánchez, E.; Morales, P.; Hurst, D. P.; Gómez-Cañas, M.; Gómez-Ruiz, M.; Pinto, D. C. G. A.; Goya, P.; Reggio, P. H.; Martin, M. I.; Fernández-Ruiz, J.; Silva, A. M. S.; Jagerovic, N. Chromenopyrazoles: non-psychoactive and selective CB1 cannabinoid agonists with peripheral antinociceptive properties ChemMedChem 2012, 7, 452-463 10.1002/cmdc.201100568
37. Morales, P.; Blasco-Benito, S.; Andradas, C.; Gómez-Cañas, M.; Flores, J. M.; Goya, P.; Fernández-Ruiz, J.; Sánchez, C.; Jagerovic, N. A selective, non-toxic CB2 cannabinoid o-quinone with in vivo activity against triple negative breast cancer J. Med. Chem. 2015, 58, 2256-2264 10.1021/acs.jmedchem.5b00078
38. Morales, P.; Vara, D.; Goméz-Cañas, M.; Zúñiga, M. C.; Olea-Azar, C.; Goya, P.; Fernández-Ruiz, J.; Díaz-Laviada, I.; Jagerovic, N. Synthetic cannabinoid quinones: Preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity Eur. J. Med. Chem. 2013, 70, 111-119 10.1016/j.ejmech.2013.09.043
39. Kotsikorou, E.; Sharir, H.; Shore, D. M.; Hurst, D. P.; Lynch, D. L.; Madrigal, K. E.; Heynen-genel, S.; Milan, L. B.; Chung, T. D. Y.; Seltzman, H. H.; Bai, Y.; Caron, M. G.; Barak, L. S.; Croatt, M. P.; Abood, M. E.; Reggio, P. H. Identi fi cation of the GPR55 Antagonist Binding Site Using a Novel Set of High-Potency GPR55 Selective Ligands Biochemistry 2013, 52, 9456-9468 10.1021/bi4008885
40. Kotsikorou, E.; Lynch, D. L.; Abood, M. E.; Reggio, P. H. Lipid bilayer molecular dynamics study of lipid-derived agonists of the putative cannabinoid receptor, GPR55 Chem. Phys. Lipids 2011, 164, 131-143 10.1016/j.chemphyslip.2010.12.003
41. Kotsikorou, E.; Madrigal, K. E.; Hurst, D. P.; Sharir, H.; Lynch, D. L.; Heynen-Genel, S.; Milan, L. B.; Chung, T. D. Y.; Seltzman, H. H.; Bai, Y.; Caron, M. G.; Barak, L.; Abood, M. E.; Reggio, P. H. Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands Biochemistry 2011, 50, 5633-5647 10.1021/bi200010k
42. Childers, S. R.; Deadwyler, S. A. Role of cyclic AMP in the actions of cannabinoid receptors Biochem. Pharmacol. 1996, 52, 819-827 10.1016/0006-2952(96)00419-4
43. Bonhaus, D. W.; Chang, L. K.; Kwan, J.; Martin, G. R. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: Evidence for agonist-specific trafficking of intracellular responses J. Pharmacol. Exp. Ther. 1998, 287, 884-888
44. Waldeck-Weiermair, M.; Zoratti, C.; Osibow, K.; Balenga, N.; Goessnitzer, E.; Waldhoer, M.; Malli, R.; Graier, W. F. Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression J. Cell Sci. 2008, 121, 1704-1717 10.1242/jcs.020958
45. Atienzar, F. A.; Gerets, H.; Tilmant, K.; Toussaint, G.; Dhalluin, S. Evaluation of impedance-based label-free technology as a tool for pharmacology and toxicology investigations Biosensors 2013, 3, 132-156 10.3390/bios3010132
46. Stolwijk, J. a.; Matrougui, K.; Renken, C. W.; Trebak, M. Impedance analysis of GPCR-mediated changes in endothelial barrier function: overview and fundamental considerations for stable and reproducible measurements Pfluegers Arch. 2015, 467, 2193 10.1007/s00424-014-1674-0
47. Ke, N.; Nguyen, K.; Irelan, J.; Abassi, Y. A.; Prazeres, D. M. F.; Martins, S. A. M. Multidimensional GPCR profiling and screening using impedance-based label-free and real-time assay Methods Mol. Biol. 2015, 1272, 215-226 10.1007/978-1-4939-2336-6-15
48. Ke, N.; Nguyen, K.; Irelan, J.; Abassi, Y. A. Multidimensional GPCR profiling and screening using impedance-based label-free and real-time assay Methods Mol. Biol. 2015, 1272, 215-26 10.1007/978-1-4939-2336-6-15
49. Henstridge, C. M.; Balenga, N. A.; Schröder, R.; Kargl, J. K.; Platzer, W.; Martini, L.; Arthur, S.; Penman, J.; Whistler, J. L.; Kostenis, E.; Waldhoer, M.; Irving, A. J. GPR55 ligands promote receptor coupling to multiple signalling pathways Br. J. Pharmacol. 2010, 160, 604-614 10.1111/j.1476-5381.2009.00625.x
50. Whyte, L.; Irving, A.; Ross, R. Pharmacological Profiling of Lysophosphatidylinositol Species at GPR55 Using xCELLigence Cellular Impedance Analysis FASEB J. 2015, 29, 772.13
51. Whyte, L.; Irving, A.; Ruth A, R. Pharmacological Profiling of GPR55 ligands Using Cellular Impedance Analysis. 25th Annual Symposium of the International Cannabinoid Research Society, Wolfville, Nova Scotia, Canada, June 28-July 3, 2015; P2-4.
52. Zhu, M.; Kim, M. H.; Lee, S.; Bae, S. J.; Kim, S. H.; Park, S. B. Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand J. Med. Chem. 2010, 53, 8760-8764 10.1021/jm1011269
53. Camps, F.; Coll, J.; Messeguer, A.; Pericás, M. A.; Ricart, S.; Bowers, W. S.; Soderlund, D. M. An Improved Procedure for the Preparation of 2,2-Dimethyl-4-chromanones Synthesis 1980, 1980, 725-727 10.1055/s-1980-29189
54. An, H.; Eum, S.-J.; Koh, M.; Lee, S. K.; Park, S. B. Diversity-oriented synthesis of privileged benzopyranyl heterocycles from s-cis-enones J. Org. Chem. 2008, 73, 1752-1761 10.1021/jo702196f
55. Brown, R. E.; Shavel, J. J. Substituted Benzopyranopyrazoles, U.S. Patent 19690826656, 1971.
56. Scott, C. W.; Peters, M. F. Label-free whole-cell assays: expanding the scope of GPCR screening Drug Discovery Today 2010, 15, 704-716 10.1016/j.drudis.2010.06.008
57. Whyte, L.; Russell, W.; Ross, R. A. Production of lysophosphatidylinositol species and GPR55 mediated signaling in osteoclasts. 25th Annual Symposium of the International Cannabinoid Research Society, Vancouver, British Columbia, Canada, June 21-26, 2013; P3-21.
58. Yamashita, A.; Oka, S.; Tanikawa, T.; Hayashi, Y.; Nemoto-Sasaki, Y.; Sugiura, T. The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55 Prostaglandins Other Lipid Mediators 2013, 107, 103-116 10.1016/j.prostaglandins.2013.05.004
59. Piñeiro, R.; Falasca, M. Lysophosphatidylinositol signalling: New wine from an old bottle Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2012, 1821, 694-705 10.1016/j.bbalip.2012.01.009
60. Balenga, N. A.; Martínez-Pinilla, E.; Kargl, J.; Schröder, R.; Peinhaupt, M.; Platzer, W.; Bálint, Z.; Zamarbide, M.; Dopeso-Reyes, I.; Ricobaraza, A.; Pérez-Ortiz, J. M.; Kostenis, E.; Waldhoer, M.; Heinemann, A.; Franco, R. Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signaling Br. J. Pharmacol. 2014, 171, 5387-5406 10.1111/bph.12850
61. Moreno, E.; Andradas, C.; Medrano, M.; Caffarel, M. M.; Pérez-Gómez, E.; Blasco-Benito, S.; Gómez-Cañas, M.; Pazos, M. R.; Irving, A. J.; Lluís, C.; Canela, E. I.; Fernández-Ruiz, J.; Guzmán, M.; McCormick, P. J.; Sánchez, C. Targeting CB2-GPR55 Receptor Heteromers Modulates Cancer Cell Signaling J. Biol. Chem. 2014, 289, 21960-21972 10.1074/jbc.M114.561761